Vontobel Holding Ltd. Grows Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Vontobel Holding Ltd. boosted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 3.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 16,957 shares of the company’s stock after acquiring an additional 600 shares during the quarter. Vontobel Holding Ltd.’s holdings in CRISPR Therapeutics were worth $797,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of CRSP. Nordea Investment Management AB boosted its stake in shares of CRISPR Therapeutics by 40.8% during the 1st quarter. Nordea Investment Management AB now owns 148,700 shares of the company’s stock valued at $10,305,000 after buying an additional 43,100 shares during the last quarter. Cetera Investment Advisers increased its position in CRISPR Therapeutics by 451.3% in the first quarter. Cetera Investment Advisers now owns 34,100 shares of the company’s stock worth $2,324,000 after buying an additional 27,915 shares during the period. CWM LLC increased its position in CRISPR Therapeutics by 11,871.1% in the second quarter. CWM LLC now owns 22,386 shares of the company’s stock worth $1,209,000 after buying an additional 22,199 shares during the period. Granite Bay Wealth Management LLC acquired a new stake in CRISPR Therapeutics in the second quarter worth $2,375,000. Finally, Principal Financial Group Inc. acquired a new position in shares of CRISPR Therapeutics during the first quarter valued at $2,758,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Trading Up 1.3 %

CRISPR Therapeutics stock opened at $48.92 on Monday. The company has a market cap of $4.15 billion, a PE ratio of -17.99 and a beta of 1.68. The company’s 50-day moving average is $47.19 and its two-hundred day moving average is $53.26. CRISPR Therapeutics AG has a 1 year low of $37.55 and a 1 year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, August 5th. The company reported ($1.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.06). The firm had revenue of $0.52 million during the quarter, compared to the consensus estimate of $12.31 million. During the same quarter in the prior year, the business posted ($0.98) earnings per share. The firm’s revenue for the quarter was down 99.3% compared to the same quarter last year. Research analysts forecast that CRISPR Therapeutics AG will post -5.6 EPS for the current year.

Wall Street Analysts Forecast Growth

CRSP has been the subject of several research reports. Rodman & Renshaw initiated coverage on shares of CRISPR Therapeutics in a report on Friday, August 2nd. They set a “buy” rating and a $90.00 price target for the company. Guggenheim reiterated a “neutral” rating on shares of CRISPR Therapeutics in a research note on Friday, June 28th. Needham & Company LLC decreased their price target on shares of CRISPR Therapeutics from $88.00 to $84.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Royal Bank of Canada reduced their target price on shares of CRISPR Therapeutics from $60.00 to $53.00 and set a “sector perform” rating on the stock in a research note on Friday, October 4th. Finally, Stifel Nicolaus reduced their target price on shares of CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a research note on Tuesday, August 6th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, CRISPR Therapeutics has an average rating of “Hold” and a consensus target price of $75.19.

Insiders Place Their Bets

In other news, CEO Samarth Kulkarni sold 4,293 shares of the company’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $198,680.04. Following the completion of the sale, the chief executive officer now directly owns 226,540 shares of the company’s stock, valued at $10,484,271.20. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, CEO Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the transaction, the chief executive officer now owns 226,540 shares in the company, valued at $10,484,271.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the sale, the general counsel now directly owns 62,597 shares of the company’s stock, valued at $2,896,989.16. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 4.10% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.